- Home
- ATHA vs BNKKW Comparison
ATHA vs BNKKW Comparison
Compare ATHA & BNKKW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- BNKKW
- Stock Information
- Founded
- ATHA 2011
- BNKKW N/A
- Country
- ATHA United States
- BNKKW United States
- Employees
- ATHA N/A
- BNKKW N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- BNKKW Package Goods/Cosmetics
- Sector
- ATHA Health Care
- BNKKW Consumer Discretionary
- Exchange
- ATHA Nasdaq
- BNKKW Nasdaq
- Market Cap
- ATHA 16.1M
- BNKKW 16.9M
- IPO Year
- ATHA 2020
- BNKKW 2020
- Fundamental
- Price
- ATHA $4.11
- BNKKW $0.03
- Analyst Decision
- ATHA
- BNKKW
- Analyst Count
- ATHA 0
- BNKKW 0
- Target Price
- ATHA N/A
- BNKKW N/A
- AVG Volume (30 Days)
- ATHA 27.3K
- BNKKW N/A
- Earning Date
- ATHA 11-06-2025
- BNKKW N/A
- Dividend Yield
- ATHA N/A
- BNKKW N/A
- EPS Growth
- ATHA N/A
- BNKKW N/A
- EPS
- ATHA N/A
- BNKKW N/A
- Revenue
- ATHA N/A
- BNKKW N/A
- Revenue This Year
- ATHA N/A
- BNKKW N/A
- Revenue Next Year
- ATHA N/A
- BNKKW N/A
- P/E Ratio
- ATHA N/A
- BNKKW N/A
- Revenue Growth
- ATHA N/A
- BNKKW N/A
- 52 Week Low
- ATHA $2.20
- BNKKW N/A
- 52 Week High
- ATHA $8.26
- BNKKW N/A
- Technical
- Relative Strength Index (RSI)
- ATHA 59.40
- BNKKW N/A
- Support Level
- ATHA $3.95
- BNKKW N/A
- Resistance Level
- ATHA $4.50
- BNKKW N/A
- Average True Range (ATR)
- ATHA 0.24
- BNKKW 0.00
- MACD
- ATHA -0.05
- BNKKW 0.00
- Stochastic Oscillator
- ATHA 55.81
- BNKKW 0.00
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.